Your browser doesn't support javascript.
loading
Identification of patient-reported outcomes measures (PROMs) and patient-reported experiences measures (PREMs) in Gaucher disease in Spain.
Giraldo, Pilar; Camprodón, María; Alcolea, Paloma Cerro; Gras-Colomer, Elena; Ibarretxe, Daiana; Lakhwani, Sunil; Mora, Elvira; Calderón, María Purificación Velasco; Morales-Conejo, Montserrat.
  • Giraldo P; Hematology, Hospital Quironsalud, Zaragoza, Spain; Fundación Española para el Estudio y Tratamiento de la Enfermedad de Gaucher (FEETEG), Zaragoza, Spain. Electronic address: giraldocastellano@gmail.com.
  • Camprodón M; Rare and Inherited Metabolic Diseases Unit, Hospital Vall d'Hebron, Barcelona, Spain.
  • Alcolea PC; Hematology Service, Hospital Ramón y Cajal Madrid, Spain.
  • Gras-Colomer E; Pharmacy Service, Hospital de Manises, Valencia, Spain.
  • Ibarretxe D; Unidad de Medicina Vascular y metabolismo, Hospital Universitari Sant Joan de Reus, Universitat Rovira i Virgili, Spain; Institut Investigació Sanitària Pere Virgili (IISPV)-CERCA, Spain; Centro de Investigación Biomédica en Red en Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto
  • Lakhwani S; Hematology Department, Hospital Universitario de Canarias, Tenerife, Spain.
  • Mora E; Hematology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
  • Calderón MPV; Pharmacist, Spanish Association of Patients and Relatives of Gaucher's Disease (AEEFE, Asociación Española de Enfermos y Familiares de la Enfermedad de Gaucher), Spain.
  • Morales-Conejo M; Reference Unit for Inherited Metabolic Disease. Hospital Universitario "12 de Octubre", Madrid, Spain; Spanish Network for Biomedical Research in Rare Diseases (CIBERER), U723, Madrid, Spain.
Med Clin (Barc) ; 2024 Aug 01.
Article en En, Es | MEDLINE | ID: mdl-39095265
ABSTRACT

BACKGROUND:

Patient-reported outcome measures (PROMs) and patient-reported experiences measures (PREMs) are crucial for understanding the impact of GD on quality of life and patient's perceptions on care, but also to guide decision-making processes. Nevertheless, no specific PREMs in GD have been published, neither PROMs for Spanish GD patients have been developed.

METHODS:

Two project coordinators selected key-points to be included in a PROMs/PREMs questionnaire, and the scientific committee and a group of expert patients contributed to the initial draft. Then, 9 meetings with experts were held to discuss controversial points. After, a questionnaire with 103 items regarding symptomatology, aspects of daily life and care experience was developed. Finally, it was conducted a Delphi survey among a multidisciplinary group of experts in GD.

RESULTS:

Consensus was reached on 85 out of the 103 items. Recommendations on PROMs and PREMs regarding symptomatology, aspects of daily life and care experience were obtained. Consensus was reached on the importance of considering fatigue, concentration problems, and communication issues in GD patients using 5-step analog scales. Panelists recommended asking GD patients about the impact on social functioning and work/school performance. Finally, consensus was reached on considering care experiences, such as treatment satisfaction, treatment interruptions or transitions and healthcare professionals involved in patient's management to perceive patient's perceptions.

CONCLUSION:

This expert consensus may help developing GD-specific PROMs/PREMs for improving GD management. Properly developed and validated PROMs/PREMs may help decision-making, establishing patient-tailored therapeutic and follow-up goals.
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Idioma: En / Es Año: 2024 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Idioma: En / Es Año: 2024 Tipo del documento: Article